{"organizations": [], "uuid": "74a595a18fa0152cc85d9aaf0552f2043eb3a0a5", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-acquires-ca/brief-cipher-pharmaceuticals-acquires-canadian-rights-to-u-s-fda-approved-a-101-40-topical-solution-idUSASC09V4L", "country": "US", "domain_rank": 408, "title": "BRIEF-Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T14:08:00.000+03:00", "replies_count": 0, "uuid": "74a595a18fa0152cc85d9aaf0552f2043eb3a0a5"}, "author": "", "url": "https://www.reuters.com/article/brief-cipher-pharmaceuticals-acquires-ca/brief-cipher-pharmaceuticals-acquires-canadian-rights-to-u-s-fda-approved-a-101-40-topical-solution-idUSASC09V4L", "ord_in_thread": 0, "title": "BRIEF-Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution", "locations": [], "entities": {"persons": [{"name": "aclaris", "sentiment": "none"}], "locations": [{"name": "u.s.", "sentiment": "none"}, {"name": "u.s", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "topical solution reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 6, 2018 / 11:10 AM / in 7 minutes BRIEF-Cipher Pharmaceuticals Acquires Canadian Rights To U.S. FDA-Approved A 101 40% Topical Solution Reuters Staff 1 Min Read \nApril 6 (Reuters) - Cipher Pharmaceuticals: \n* CIPHER PHARMACEUTICALS ACQUIRES EXCLUSIVE CANADIAN RIGHTS TO U.S. FDA-APPROVED A-101 40% TOPICAL SOLUTION FROM ACLARIS THERAPEUTICS \n* CIPHER PHARMACEUTICALS INC - ACLARIS WILL RECEIVE AN UPFRONT PAYMENT OF US$1.0 MLN Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-04-06T14:08:00.000+03:00", "crawled": "2018-04-06T14:26:19.031+03:00", "highlightTitle": ""}